WO2007054600A2 - Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación - Google Patents
Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación Download PDFInfo
- Publication number
- WO2007054600A2 WO2007054600A2 PCT/ES2006/070171 ES2006070171W WO2007054600A2 WO 2007054600 A2 WO2007054600 A2 WO 2007054600A2 ES 2006070171 W ES2006070171 W ES 2006070171W WO 2007054600 A2 WO2007054600 A2 WO 2007054600A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erythropoietin
- combination
- glycoisoforms
- cell line
- sialic acid
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 236
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 234
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 234
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 234
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 68
- 230000002265 prevention Effects 0.000 title claims abstract description 29
- 208000013223 septicemia Diseases 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 230000009261 transgenic effect Effects 0.000 title claims description 12
- 238000000034 method Methods 0.000 claims abstract description 82
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 58
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 31
- 239000001963 growth medium Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 19
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 102000044890 human EPO Human genes 0.000 claims description 18
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 10
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 9
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 9
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 9
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 9
- 235000019270 ammonium chloride Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000003805 procoagulant Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 230000002641 glycemic effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 238000011210 chromatographic step Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- -1 chewables Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 38
- 239000000243 solution Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 17
- 102000001708 Protein Isoforms Human genes 0.000 description 17
- 108010029485 Protein Isoforms Proteins 0.000 description 17
- 108010074604 Epoetin Alfa Proteins 0.000 description 15
- 108010027485 asialoerythropoietin Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000001155 isoelectric focusing Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000010437 erythropoiesis Effects 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000873785 Homo sapiens mRNA-decapping enzyme 1A Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000000913 erythropoietic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 102100035856 mRNA-decapping enzyme 1A Human genes 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 235000004251 balanced diet Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001361 thrombopoietic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038481 Renal necrosis Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940005036 ketamine 50 mg/ml Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229940110150 xylazine 20 mg/ml Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Definitions
- glycoisoforms for the treatment or prevention of septicemia transgenic cell line producing erythropoietin glycoforms
- pharmaceutical composition comprising said combination, procedures for obtaining the cell line, procedure for producing said combination of glycoisoforms and methods of treatment and prevention of septicemia
- the present invention relates to a transgenic cell line producing a combination of erythropoietin glycoforms, wherein said glycoisoforms may comprise an amount of sialic acid of between 4 to 10 sialic acid molecules per erythropoietin molecule, the combination of glycoisoforms for the treatment or prevention of septicemia, a pharmaceutical composition comprising said combination, procedures for obtaining the cell line, procedure for producing said combination of glycoisoforms and methods of treatment and prevention of septicemia.
- EPO Human erythropoietin
- erythropoietin a protein widely used to stimulate erythropoiesis, in its natural and recombinant form (produced in transgenic lines of eukaryotic cells) contains four complex chains of oligosaccharides linked to the polypeptide chain, three of them in unions of type N and one in a union of type O, whose specific location is well known (Elliott, S. et. al .; The Journal of Biological Chemistry, 279 (16): 16854-16862, 2004; Watson et al, Glycobiology 4 (2): 227-237, 1994).
- Oligosaccharides with N-type junctions may contain a variable number of sialic acid terminal residues and this significantly affects EPO activity (Egrie, J. and Browne, J., Br. J. Cancer, 84 (l): 3 -10, 2001; Goldwasser et al, J. Biol. Chem. 249: 4202-4206, 1974).
- a major Sialic acid content prolongs the half-life of EPO in the blood but decreases the affinity for the receptor related to its hematopoietic activity.
- an EPO with a lower content of sialic acid or lacking it has a low 'in vivo' half-life and a high affinity for the receptor related to its hematopoietic activity.
- EPO glycoisoforms Each of these EPO glycoisoforms can be isolated from the rest because they have a different charge, for example by means of the isoelectric focusing technique.
- the mixture of EPO glycoisoforms produced by recombinant cells may be different according to the cell line used. For example, when EPO is produced in CHO cells, glycoisoforms contain from 1 to 14 sialic acid molecules.
- 2002/0169129 discloses a method comprising ad- minister an effective dose of recombinant human EPO to improve the quality of life of a patient.
- the patent application of Campana W. M: et al., US No. 2004/0018978 discloses a method of treatment of neuropathic pain and protection of the peripheral nervous system comprising administering erythropoietin.
- US Patent No. 6,268,336 discloses a method of treating liver diseases that comprises administering erythropoietin.
- WO 03/057242 of Van Gilst, WH et al. Discloses the use of erythropoietin for the treatment or prevention of cardiac deficiencies.
- 6,784,154 to Westenfelder Ch discloses a method for renal protection and the treatment of acute ischemic renal failure comprising administering erythropoietin.
- WO 04/012759 of Haller H. et al . discloses the use of erythropoietin for stimulation, mobilization, proliferation and differentiation of endothelial precursor cells.
- Sepsis is the systemic response to infection. This response can sometimes be exacerbated and affect the functioning of organs such as: kidney, liver, heart, lung, intestine, pancreas, CNS, adrenal and bone marrow, it can also alter metabolism, coagulation, immune system, Regional perfusion of the organs and systemic circulation causing septic shock.
- organs such as: kidney, liver, heart, lung, intestine, pancreas, CNS, adrenal and bone marrow, it can also alter metabolism, coagulation, immune system, Regional perfusion of the organs and systemic circulation causing septic shock.
- Sepsis mortality increases directly proportional to the presence and severity of shock and the number of organ failures and ranges from 30% in the absence of them to 100% when four or more organs are compromised (Fry DE, Pearlstein L, Fulton RL et al, Multiple system organ failure.The role of uncontrolled infection.Arch Surg 115: 136-140, 1980) .In spite of the developments achieved, sepsis remains the most important cause of mortality in the Care units Non-coronary intensive (Angus DC, ET. AL. Crit Care Med; 29: 1303-10, 2001).
- lymphocyte loss due to apoptosis may be responsible for the marked immunosuppression that is frequently observed in septic patients (Wang SD, et al., J Immunol; 152: 5014-21, 1994).
- Other cell types such as hepatocytes (Rogers HW, et. Al., J Immunol; 156: 679-84, 1996), columnar epithelial cells of the intestinal tract (Hotchkis RS, et.
- Said combination may lack any of said glycoisoforms or may be constituted by different proportions of each glycoisoform.
- Erythropoietin is human erythropoietin and can be a natural, recombinant erythropoietin, analogs, mimics, mimetics, or fragments thereof.
- Said combination of erythropoietin has therapeutic and preventive activity in septicemia.
- Erythropoietin is human erythropoietin and can be a natural, recombinant erythropoietin, analogs, mimetics, mimics, or fragments thereof.
- the cell line is a CHO cell line and even more preferably the cell line is the AB2H52 cell line deposited in the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under the accession number DSM ACC2727.
- DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen
- the combination of produced and purified erythropoietin has therapeutic activity as an agent for the treatment and prevention of sepsis.
- Erythropoietin is human erythropoietin and can be a natural, recombinant erythropoietin, analogs, mimetics, mimics, or fragments thereof.
- Said composition may comprise any excipient known in the art of drug production.
- [16] b.purify and isolate the combination of erythropoietin glycoisoforms.
- the cell line culture can be carried out in a medium comprising additives such as N-acetylglucosamine, ammonium chloride, sodium chloride or combinations thereof and where the purification and isolation step of the combination of Erythropoietin is carried out by at least one chromatographic stage.
- the Erythropoietin combination comprises an isoelectric point profile between 4 and 5.3.
- the culture medium has an osmolality of between 310 and 450 milliosmol / kg of solvent.
- Said combination may lack any of said glycoisoforms or may be constituted by different proportions of each glycoisoform.
- Erythropoietin is human erythropoietin and can be a natural, mimetic, recombinant erythropoietin, analogs, mimics, or fragments thereof.
- the method comprises the steps of:
- the culture medium has an osmolality of between 310 and 450 milliosmol / kg of solvent.
- Said combination may lack any of said glycoisoforms or may be constituted by different proportions of each glycoisoform.
- Erythropoietin is human erythropoietin and can be a natural, recombinant erythropoietin, analogs, mimetics, mimics, or fragments thereof.
- the method can be carried out by administering a dose between 10 ⁇ g / Kg and 1000 ⁇ g / Kg for an adult of 70 kg of the combination of human recombinant erythropoietin glycoisoforms of this invention.
- This combination may lack any of said glycoisoforms or may be constituted by different proportions of each glycoisoform.
- Erythropoietin is human erythropoietin and can be a natural, recombinant erythropoietin, analogs, mimetics, mutants, or fragments thereof.
- the method can be carried out by administering a dose between 10 ⁇ g / Kg and 1000 ⁇ g / Kg for a 70 kg mammal of the erythropoietin combination of the present invention.
- Figure 1 The restriction map of the plasmid used in the transfection of the CHO.K1 cell line is shown in the figure;
- Figure 2A shows an SDS-PAGE stained with Coomasie Blue
- FIG. 2B shows the Western Blota bands. starting from the gel of figure 2A;
- Figure 2C is the graphical representation of the distance migrated by each molecular weight (PM) pattern as a function of the logarithm of the PM.
- lane 1 corresponds to 25 ⁇ g of commercial EPO (Eprex, Cilag-Jansen);
- lane 2 corresponds to 25 ⁇ g of the erythropoietin of the invention
- lane 3 corresponds to PM patterns (BioRad, USA)
- lane 4 corresponds to 5 ⁇ g commercial EPO (Eprex, Cilag-Jansen)
- lane 5 corresponds to 5 ⁇ g of the erythropoietin of the invention;
- Figure 3 shows the bands of the isoelectric focusing test stained with Coomasie Blue.
- Lane 1 corresponds to Asialo-EPO
- Lane 2 corresponds to the erythropoietin of the invention
- lane 3 corresponds to commercial erythropoietin (Eprex, Cilag-Jansen)
- lane 4 corresponds to pl patterns (Amersham Bioscience).
- Figure 3B is a graphical representation of the pl as a function of the migration distance of each pl obtained;
- Figure 4 shows survival curves of mice with experimentally provoked sepsis. The animals received 1 hour before a ligation and double puncture of the cecum (LPC) dose of 5 ⁇ g / kg, 15 ⁇ g / kg, 30 ⁇ g / kg or 50 ⁇ g / kg of the combination of EPO glycoisoforms of the invention or Placebo (Control).
- LPC cecum
- Figure 5 shows survival curves of mice with experimentally induced sepsis. The animals received 1 hour before the LPC dose of 15 ⁇ g / kg, 30 ⁇ g / kg or 50 ⁇ g / kg of commercial EPO (Eprex, Cilag-Jansen) or Placebo (Control).
- EPO Eprex, Cilag-Jansen
- Placebo Control
- Figure 6 shows survival curves of mice with experimentally induced sepsis. The animals received a dose of 15 ⁇ g / kg, 30 ⁇ g / kg or 50 ⁇ g / kg of Asialo-EPO or Placebo (Control) 1 hour before the LPC.
- Figure 7 shows the frequency of general histopathological lesions in septic mice treated preventively with 50 ⁇ g of commercial EPO or with 50 ⁇ g of the EPO combination of the invention.
- Figure 8 shows survival curves of mice with experimentally induced sepsis. Animals received 1 hour after the LPC dose of 15 ⁇ g / Kg, 30 ⁇ g / Kg or 50 ⁇ g / Kg of the combination of EPO glycoisoforms of the invention or Placebo (Control).
- the erythropoietin of the invention refers to a set or combination of erythropoietin glycoisoforms.
- An erythropoietin glycoisoform is defined as an erythropoietin having a single isoelectric point (pl). Different glycoisoforms have the same amino acid sequence but differ in their pl.
- transgenic eukaryotic cell lines are provided, preferably transgenic cell lines expressing erythropoietin, particularly a combination of erythropoietin glycoisoforms, wherein said combination comprises glycoisoforms comprising 4 sialic acid molecules per erythropoietin molecule. to isoforms comprising 10 molecules of sialic acid per molecule of erythropoietin. For example glyco-forms comprising 4, 5, 6, 7, 8, 9 and / or 10 sialic acid molecules per erythropoietin molecule.
- the eukaryotic cell line can be, without limiting it to, mammalian cell lines such as the CHO, Vero, MDCK lines, preferably the eukaryotic cell line is the CHO line and more preferably it is the AB2H52 transgenic cell line deposited under Treaty from Budapest on June 22, 2005 in the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under the DSM access number ACC2727.
- mammalian cell lines such as the CHO, Vero, MDCK lines
- the eukaryotic cell line is the CHO line and more preferably it is the AB2H52 transgenic cell line deposited under Treaty from Budapest on June 22, 2005 in the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under the DSM access number ACC2727.
- the erythropoietin produced by the cell line of the invention includes but is not limited to erythropoietin mutations such as those having altered amino acids at the carboxy terminal end (see US Patent No. 5,457,089, incorporated here entirely as a reference), analogs; peptides that bind to the receptor; small molecules that mimic erythropoietin referred to herein as mimetics (US Patent No. 2002/0016350, incorporated herein entirely by reference); natural erythropoietin; imitators, for example those modified in order to reduce their immunogenicity (US Patent No.
- erythropoietin with any amino acid skeleton as long as the cell line produces glycoisoforms comprising between 4 and 10 sialic acid molecules per molecule of erythropoietin.
- the amino acid skeleton of erythropoietin may be SEQ ID No. 1.
- the cell line of the invention was obtained by transfecting CHO.K1 cells with the plasmid shown in Figure 1.
- the cells selected in culture that produced erythropoietin were cloned and the combination of glycoisoforms produced by Western blot of isoelectric focusing was evaluated. followed by a band densitometry test.
- the cell line of the present invention can be obtained by selecting the clones that produce the combination of erythropoietin glycoisoforms of the invention.
- the selected cell line can be cultured in the presence of ammonium chloride, sodium chloride, N-acetylglucosamine or combinations thereof to induce the production and release of the combination of erythropoietin glycoisoforms of the invention (glyco-forms 4 to 10 combined in different proportions, one or more of the glycoisoforms being absent in the combination).
- the combination of glycoisoforms may comprise an amount of between 2 and 12% of glycoisoform 4, between 5 and 25% of glycoisoform 5, between 9 and 34% of glycoisoform 6, between 9 and 34% of glycoisoform 7, between 10 and 35% of the glycoisoform 8, between 2 and 23% of the glycoisoform 9 and between 0 and 2% of the glycoisoform 10.
- the isoelectric point (pl) of the erythropoietin of the invention Asialo erythropoietin and commercial erythropoietin (Eprex, Cilag-Jansen).
- the erythropoietin street (1) shows only bands a and b corresponding to a pl of 6.7 and 6.6 respectively.
- Lane 2 where the erythropoietin of the invention was seeded shows the bands from c to i corresponding to a pl between 4.0 and 5.3. Street 3 where the commercial EPO was planted shows bands from j to m corresponding to a pl between 3.5 and 4.3.
- Erythropyetine of the invention 7.6 moles of sialic acid / mole of polypeptide.
- Asialo-EPO 4.4 moles of sialic acid / mole polypeptide.
- Commercial EPO (Eprex, Cilag-Jansen): 11.3 moles of sialic acid / mole polypeptide.
- the pl, percentages and sialic acid content of each glycoisoform of the erythropoietin of the invention was determined by the isoelectric focusing technique (Table 1). The sialic acid content of each of the glycoisoforms is shown in the following table:
- the combination of the invention may comprise any proportion of glycoisoforms of each of the isoforms 4, 5, 6, 7, 8, 9, and 10; and all of them combined in different ways are within the scope of the present invention.
- one or more of the glycoisoforms may be absent or the proportion of each glycoisoform present in the combination could be different. All these variants are within the scope of the present invention.
- Sham group refers to animals that underwent simulated surgery to assess surgical stress).
- EPO of the invention can be used at higher doses are to produce thrombopoietic effect.
- Commercial EPO (Eprex, Cilag-Jansen) decreased mortality when administered at a dose of 15 ⁇ g / Kg ( Figure 5).
- commercial EPO was not effective, increasing mortality due to the damage caused by the increase in erythropoiesis and its consequent thrombopoietic effect.
- Asialo-EPO did not reduce mortality in all doses studied ( Figure 6).
- erythropoietin may prevent or be useful for the treatment of sepsis as long as said erythropoietin is not Asialo-EPO.
- any combination of erythropoietin glycoisoforms or a single glycoisoform is useful for the treatment and prevention of septicemia, septic shock and other disorders such as severe hypovolemic shock or cardiogenic origin, and other non-infectious causes such as polytrauma, pancreatitis, severe burns, and those caused by toxic agents, hypoxia, ischemia or necrosis among others.
- the combination of glycoisoforms for the treatment and prevention of septicemia is the combination comprising glycoisoforms of 4, 5, 6, 7, 8, 9 or 10 sialic acid molecules per erythropoietin molecule. More preferably it is the combination of glycoisoforms that releases the cell line of the present invention to the culture medium.
- Table 5 shows that the incidence of severe renal damage (severe congestion, acute tubular necrosis or focal renal necrosis) was as follows: Control: 28.5%, commercial EPO: 14.2%, EPO combination of the invention: no renal lesions were observed . 25% in the control group, 37.5% in the commercial EPO group and 12.5% in the group of animals treated with the EPO combination of the invention presented hepatic involvement (severe congestion or necrosis).
- mice of the group treated with the combination of isoforms of the present invention had no cardiac lesions, while 37.5% of the control group and 25% of the group of animals treated with commercial EPO had myocardial damage (congestion). No mice had brain injury, except for an animal from the control group that presented inflammatory infiltrate.
- the invention also encompasses a pharmaceutical composition for the treatment of septicemia or other related disorders.
- the pharmaceutical composition for the treatment or prevention of septicemia comprises different combinations of erythropoietin glycoisoforms, for example a combination of glycoisoforms, wherein said combination comprises glycoisoforms of 4, 5, 6, 7, 8, 9 or 10 sialic acid molecules per erythropoietin molecule, where one or more glycoisoforms may be absent in said combination or said combination may comprise different proportions in each glycoisoform. More preferably it is the combination of glycoisoforms that releases the cell line of the present invention to the culture medium; and excipient known in the state of the art.
- composition of the invention may be made in the form of, for example, tablets, tablets, capsules, particles; sublingual, intranasal, injectable or other forms known in the art, all of which are within the scope of the present invention.
- composition of the present invention may comprise each
- Example 1 Obtaining an erythropoietin-producing cell line.
- the CHO.K1 cell line (ATCC CCL-61) was used.
- the culture medium called Medium 1 (consisting of a 1: 1 mixture of D-MEM (Gibco) and Ham's F12 (Gibco) media supplemented with sodium bicarbonate (Gibco) 2,441 was used for the growth and maintenance stages.
- the cells were transfected with the plasmid called pnrepo ( Figure 1), obtained from cloning the human erythropoietin gene into the commercial eukaryotic expression plasmid pClneo.
- Transfected cells were selected using the antibiotic Neomycin and the producer cell lines were analyzed using the immunodot assay.
- Example 2 Evaluation of the glycosylation pattern of the glycoisoforms produced.
- the electrophoretic support was prepared using the acrylamide / bisacrylamide mixture in a concentration of 8% (P / V) with the addition of 7 M urea and ampholytes to generate a pH range between 3 and 10.
- Example 3 Obtaining clones of erythropoietin producing cells with low sialic acid content.
- Example 4 enrichment and purification of human erythropoietin isoforms with lower sialic acid content.
- the culture supernatant was filtered in cartridges with a pore size of 3-0.8 ⁇ m and sequentially in cartridges with a pore size of 0.8-0.45 ⁇ m ( PaIl Technology, USA), using a pressure of less than 0.5 kgf / cm.
- the filtered crop was immediately processed.
- the elution product was concentrated to a volume of between 75 and 100 ml and a buffer change was made with 20 mM Tris solution pH 6.5 using a Pellicon tangential ultrafiltration system (Millipore, USA) with cartridges 10 kDa pore size and 0.1 m surface. It was diafiltered using 10 times the volume of the concentrate. The obtained product was stored at -20 0 C or immediately processed.
- the apparent molecular weight was determined by interpolation of the distance migrated by each sample in a graphical representation of the distance migrated by each marker based on its molecular weight.
- the electrophoretic support was prepared using a mixture of acrylamide / bisacrylamide in a concentration of 8% (P / V) with the addition of 7 M urea and ampholytes to generate a pH gradient between 3 and 10.
- the gel It was pre-focused for 1 hour at 2000 V - 100 mA - 10 W. Subsequently, 20 ⁇ g of the different EPO preparations were seeded in a volume of 20 ⁇ l, proceeding to focus for 40 minutes using the same conditions indicated above. As controls, isoelectric point markers (GE Healthcare) were planted.
- the apparent isoelectric point was determined by interpolation of the distance migrated by each sample in a graphic representation of the distance migrated by each marker based on its isoelectric point.
- Example 6 In vitro analysis of the biological activity of erythropoietin
- Glutamine (Fluka, Germany) 200 mM, 0.75g NaHCO3 (Gibco, USA), 50mg / ml gentamicin (Parafarm, Argentina), sterilized by filtration through 0.22mm pore filters; supplemented with 10% V / V fetal bovine serum (SFB) (Bioser, Argentina), 5ml 5mM deb-mercaptoethanol (Merck, Germany), and 5ng / ml rhGM-CSF (Growgen, Bioprofarma S.A., Argentina.
- V / V fetal bovine serum (SFB)
- 5ml 5mM deb-mercaptoethanol (Merck, Germany)
- 5ng / ml rhGM-CSF Crowgen, Bioprofarma S.A., Argentina.
- Test medium Growth culture medium lacking rhGM-CSF.
- Washing medium Growth culture medium lacking rhGM-CSF and
- 50 ml of the cell suspensions were seeded in each cavity of a 96-well plate (except in the wells corresponding to the color reagent control) and were added: 50 ⁇ l of the purified erythropoietin of the invention according to Example 4, 50 ⁇ l of a commercial erythropoietin (Eprex, Cilag-Jansen) (7500 mU / ml) in serially diluted dilutions such that the curve concentrations will vary between 15 and 2000 mU / ml, 50 ⁇ l of Asialo EPO and 50 ⁇ l of test medium as appropriate. The plates were incubated at 37 ° C for 72 hours.
- [122] -control positive 50ml of test medium, supplemented with 7500 mU / ml of
- FBCB-UNL with free access to water and balanced diet.
- the temperature of the sector was maintained at 23 ° C.
- the lighting regime was 12 hours. light - 12 hours. darkness.
- the animals were randomly divided into 3 groups of 6 animals. Each group was also divided into 3 subgroups of 2 animals each. Each subgroup was kept in separate cages.
- the animals were anesthetized through intramuscular injection of a mixture of 140 ⁇ l of Ketamine 50 mg / ml and 75 ⁇ l of Xylazine 20 mg / ml. Once anesthetized, the animals were inoculated with an injection into the main vein of the tail. Each animal was injected with 500 ⁇ g of the corresponding erythropoietin according to treatment scheme, in a volume of 500 ⁇ l of solution, using tuberculin syringes provided with 29g needles.
- the plasma concentration of the different erythropoietins injected was determined by a sandwich ELISA (Amadeo, I., et al., J. Immunol. Meth. 293: 191-205,
- A are already constants of the initial phase that reflect the distribution of erythropoietin in all intracellular fluids of the animal
- B and ⁇ are constants of the elimination phase related to actual plasma clearance (Donahue et al., Cold Spring Harbor Symp Quant. Biol. 51, 685-692, 1986, incorporated herein by reference in its entirety).
- These constants were estimated from the empirical data using computer tools (Microcal TM Origin TM Version 5.0, Microcal Software, USA).
- the half-life of distribution (T ⁇ ), the half-life of elimination (T ⁇ ) and total plasma clearance (CL) were calculated using equations (2), (3) (4), respectively:
- Dilutions of the sample to be analyzed were made using a phosphate / albumin buffer pH 7.2.
- the buffer was prepared according to the following instructions: dissolve 10.75 g of disodium acid phosphate and 7.6 g of sodium chloride in 900 ml of distilled water; add 5 ml of a concentrated solution of human albumin 200 mg. / mi and complete with distilled water c.s.p. a final volume of 1,000 mi. Adjust the pH to 7.2 with dilute sodium hydroxide solution or with dilute phosphoric acid.
- mice were anesthetized with sodium pentothal (3 mg / 0.5 ml / mouse) and bled through the retrorbital sinus, using heparinized capillaries. The blood was transferred to Eppendorf tubes with 5 ⁇ l of sodium heparin.
- the reticulocytes were quantified by taking 5 ⁇ l of a reticulocyte buffer pH 7.2.
- the buffer was prepared according to the following protocol: dissolve 10.75 g of disodium acid phosphate, 7.6 g of sodium chloride, 0.2 g of sodium azide and 0.74 g of EDTA in distilled water and then bring to volume end of 1,000 mi. Adjust the pH to 7.2.
- Example 9 Evaluation of the erythropoietin of the invention as an active ingredient for the treatment of sepsis, and determination of the appropriate dose.
- mice Female CfI mice of 5 to 7 weeks of age, approximately 25-3Og in weight, were used.
- mice were anesthetized intraperitoneally with ketamine / Xylazine (133: 10 ug / g mouse) (Holliday® 50 mg / ml ketamine and Narcoxil® 20 mg / ml xylazine). Subsequently, a minimal medial laparotomy was performed. The cecum was ligated with surgical suture 1 cm from its distal end, taking care not to obstruct the ileocecal valve. Two holes were made with an 18g needle in the blind distal to the ligation site. The blind was compressed so that a small amount of enteric content passed through the holes, the blind was introduced into the peritoneal cavity and the abdominal wall was closed in two planes. Finally, to ensure hydration of the mice, 1 ml of 0.9% saline was injected subcutaneously and from there all animals had free access to water and food.
- ketamine / Xylazine 133: 10 ug / g mouse
- mice were treated with sepsis.
- the animals of the first group received 50 ⁇ g of commercial EPO (Eprex, Cilag-Jansen) subcutaneously, the second group 50 ⁇ g of the preparation of the invention and the third group equal volume of physiological solution long before the LPC.
- the mice were sacrificed randomly within the first six days of the LPC.
- the following organs were evaluated by a histopathological study using the hematoxylin-eosin technique: brain, heart, lung, intestine, liver and kidney. Based on the histopathological study, the associated lesions were established for each organ and for each animal. The histopathological analysis was performed independently and blindly.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2008006159A MX2008006159A (es) | 2005-11-10 | 2006-11-07 | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composiciones farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea |
AU2006313672A AU2006313672B2 (en) | 2005-11-10 | 2006-11-07 | Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical composition comprising such combination, procedures to obtain the cell line, procedures to produce such combination of glycoisoforms, and sepsis treatment and prevention methods |
EP06820043A EP1947115B1 (en) | 2005-11-10 | 2006-11-07 | Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination, method of obtaining the cell line, method of producing the combination of glycoisoforms and methods for the treatment and prevention of septicaemia |
US12/093,365 US8343917B2 (en) | 2005-11-10 | 2006-11-07 | Combination of erythropoietin glycoisoforms |
CA2629304A CA2629304C (en) | 2005-11-10 | 2006-11-07 | Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination |
ES06820043T ES2396439T3 (es) | 2005-11-10 | 2006-11-07 | Combinación de glicoisoformas para el tratamiento o la prevención de la septicemia, línea celular transgénica que produce glicoisoformas de eritropoyetina, composición farmacéutica que comprende dicha combinación, procedimiento para obtener la línea celular, procedimiento para producir la combinación de glicoisoformas y procedimientos para el tratamiento y la prevención de la septicemia |
BRPI0618498-7A BRPI0618498A2 (pt) | 2005-11-10 | 2006-11-07 | combinação de glicoisoformas para o tratamento ou a prevenção da septicemia, linha celular transgênica produtora de glicoformas de eritropoietina, composição farmacêutica incluindo tal combinação, procedimentos para obtenção da linha celular, procedimentos para produção de tal combinação de glicoisoformas e métodos para tratamento e prevenção da septicemia |
IL191279A IL191279A (en) | 2005-11-10 | 2008-05-06 | Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical compositions comprising such combination, procedures to obtain the cell line and procedures to produce such combination of glycoisoforms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP050104712A AR053416A1 (es) | 2005-11-10 | 2005-11-10 | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
ARP050104712 | 2005-11-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007054600A2 true WO2007054600A2 (es) | 2007-05-18 |
WO2007054600A3 WO2007054600A3 (es) | 2007-07-19 |
WO2007054600B1 WO2007054600B1 (es) | 2007-10-18 |
Family
ID=38023621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2006/070171 WO2007054600A2 (es) | 2005-11-10 | 2006-11-07 | Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación |
Country Status (12)
Country | Link |
---|---|
US (1) | US8343917B2 (es) |
EP (1) | EP1947115B1 (es) |
AR (1) | AR053416A1 (es) |
AU (1) | AU2006313672B2 (es) |
BR (1) | BRPI0618498A2 (es) |
CA (1) | CA2629304C (es) |
ES (1) | ES2396439T3 (es) |
IL (1) | IL191279A (es) |
MA (1) | MA30010B1 (es) |
MX (1) | MX2008006159A (es) |
WO (1) | WO2007054600A2 (es) |
ZA (1) | ZA200805044B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457089A (en) | 1989-07-20 | 1995-10-10 | Behringwerke Aktiengesellschaft | Muteins of human erythropoietin, the preparation thereof and the use thereof |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6268336B1 (en) | 1996-06-20 | 2001-07-31 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of hepatic diseases |
US20020016350A1 (en) | 1998-04-20 | 2002-02-07 | Connolly Peter J. | Substituted amino acids as erythropoietin mimetics |
US20020169129A1 (en) | 1998-02-04 | 2002-11-14 | Zaharia Veronica C. | Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO) |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
WO2003057242A1 (en) | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
WO2003080852A1 (en) | 2002-03-26 | 2003-10-02 | Lek Pharmaceutical And Chemical Company D.D. | Process for the preparation of a desired erythropoietin glyco-isoform profile |
US6673575B1 (en) | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
US20040018978A1 (en) | 2002-06-05 | 2004-01-29 | Campana W Marie | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
WO2004012759A2 (de) | 2002-07-26 | 2004-02-12 | Epoplus Gmbh & Co. Kg | Erythropoetin zur stimulation endothelialer voläuferzellen |
US20040063917A1 (en) | 2001-02-06 | 2004-04-01 | Carr Francis J. | Modified erythropoietin (epo) with reduced immunogenicity |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US20040198663A1 (en) | 2003-04-04 | 2004-10-07 | Baker John E. | Method of treating cardiac ischemia by using erythropoietin |
US20040266690A1 (en) | 2003-05-30 | 2004-12-30 | Chadler Pool | Formation of novel erythropoietin conjugates using transglutaminase |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL77081A (en) * | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
BR9917606A (pt) * | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
EP1533380B1 (en) * | 1999-04-15 | 2009-11-04 | Crucell Holland B.V. | Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
CA2465007C (en) * | 2001-10-29 | 2012-01-17 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
AU2002356749A1 (en) * | 2001-11-28 | 2003-06-10 | Hermann Katinger | Process for the production of polypeptides in mammalian cell cultures |
BR0214489A (pt) | 2001-11-28 | 2004-10-19 | Sandoz Ag | Processo para a produção de um polipeptìdeo recombinante |
-
2005
- 2005-11-10 AR ARP050104712A patent/AR053416A1/es unknown
-
2006
- 2006-11-07 MX MX2008006159A patent/MX2008006159A/es active IP Right Grant
- 2006-11-07 CA CA2629304A patent/CA2629304C/en not_active Expired - Fee Related
- 2006-11-07 EP EP06820043A patent/EP1947115B1/en not_active Not-in-force
- 2006-11-07 WO PCT/ES2006/070171 patent/WO2007054600A2/es active Application Filing
- 2006-11-07 BR BRPI0618498-7A patent/BRPI0618498A2/pt not_active IP Right Cessation
- 2006-11-07 ZA ZA200805044A patent/ZA200805044B/xx unknown
- 2006-11-07 US US12/093,365 patent/US8343917B2/en not_active Expired - Fee Related
- 2006-11-07 ES ES06820043T patent/ES2396439T3/es active Active
- 2006-11-07 AU AU2006313672A patent/AU2006313672B2/en not_active Ceased
-
2008
- 2008-05-06 IL IL191279A patent/IL191279A/en not_active IP Right Cessation
- 2008-05-09 MA MA30921A patent/MA30010B1/fr unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457089A (en) | 1989-07-20 | 1995-10-10 | Behringwerke Aktiengesellschaft | Muteins of human erythropoietin, the preparation thereof and the use thereof |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US6268336B1 (en) | 1996-06-20 | 2001-07-31 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of hepatic diseases |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6673575B1 (en) | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
US20020169129A1 (en) | 1998-02-04 | 2002-11-14 | Zaharia Veronica C. | Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO) |
US20020016350A1 (en) | 1998-04-20 | 2002-02-07 | Connolly Peter J. | Substituted amino acids as erythropoietin mimetics |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US20040063917A1 (en) | 2001-02-06 | 2004-04-01 | Carr Francis J. | Modified erythropoietin (epo) with reduced immunogenicity |
US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
WO2003057242A1 (en) | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
WO2003080852A1 (en) | 2002-03-26 | 2003-10-02 | Lek Pharmaceutical And Chemical Company D.D. | Process for the preparation of a desired erythropoietin glyco-isoform profile |
US20040018978A1 (en) | 2002-06-05 | 2004-01-29 | Campana W Marie | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
WO2004012759A2 (de) | 2002-07-26 | 2004-02-12 | Epoplus Gmbh & Co. Kg | Erythropoetin zur stimulation endothelialer voläuferzellen |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
US20040198663A1 (en) | 2003-04-04 | 2004-10-07 | Baker John E. | Method of treating cardiac ischemia by using erythropoietin |
US20040266690A1 (en) | 2003-05-30 | 2004-12-30 | Chadler Pool | Formation of novel erythropoietin conjugates using transglutaminase |
Non-Patent Citations (32)
Title |
---|
AMADEO, I. ET AL., J. IMMUNOL. METH., vol. 293, 2004, pages 191 - 205 |
ANGUS, D.C. ET AL., CRIT. CARE MED., vol. 29, 2001, pages 1303 - 10 |
BERNARD, G.; VINCENT, J.L.; LATERRE, P.F. ET AL.: "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis", N. ENG. J. MED., vol. 344, 2001, pages 699 - 609 |
BERNARD, G.R.; MARGOLIS, B.D.; SHANIES, H.M. ET AL.: "Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)", CHEST., vol. 125, 2004, pages 2206 - 2216 |
BEVILACQUA, M.; NELSON, R., J. CLIN. INVEST., vol. 91, 1993, pages 379 - 387 |
DELLINGER, P. ET AL., CRIT. CARE MED., vol. 32, 2004, pages 858 - 73 |
DONAHUE ET AL., COLD SPRING HARBOR SYMP QANT. BIOL., vol. 51, 1986, pages 685 - 692 |
EGRIE, J.; BROWNE, J., BR. J. CANCER, vol. 84, no. 1, 2001, pages 3 - 10 |
ELLIOTT, S. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 16, 2004, pages 16854 - 16862 |
FRY, D.E.; PEARLSTEIN, L.; FULTON, R.L. ET AL.: "Multiple System Organ Failure", THE ROLE OF UNCONTROLLED INFECTION, ARCH. SURG., vol. 115, 1980, pages 136 - 140 |
FUKUDA ET AL., BLOOD, vol. 73, 1989, pages 84 - 89 |
GOLDWASSER ET AL., J. BIOL. CHEM., vol. 249, 1974, pages 4202 - 4206 |
GOOCHE ET AL., BIOFTECHNOLOGY, vol. 9, 1991, pages 1347 - 1355 |
HAIMOVITZ-FRIEDMAN, A. ET AL., J. EXP. MED., vol. 186, 1997, pages 1832 - 41 |
HART, CURR. OP. CELL BIOL., vol. 4, 1992, pages 1017 - 1023 |
HIGUCHI ET AL., J. BIOL. CHEM., vol. 267, no. 11, 1991, pages 7703 - 7709 |
HOTCHKIS, R.S. ET AL., CRIT. CARE MED., vol. 25, 1997, pages 1298 - 1307 |
HOTCHKIS, R.S. ET AL., CRIT. CARE MED., vol. 27, 1999, pages 1230 - 517 |
IMAI ET AL., EUR. J. BIOCHEM., vol. 194, 1990, pages 457 - 462 |
IMAI ET AL., NATURE, vol. 361, 1993, pages 555 - 557 |
LAEMMLI, U.K: "Cleavage of structural proteins during the assembly of the head of bacteriophage T4", NATURE, vol. 227, 1970, pages 680 - 685, XP055108426, DOI: doi:10.1038/227680a0 |
MORISHITA, E. ET AL., NEUROSCIENCE, vol. 76, 1997, pages 105 - 116 |
NELSON ET AL., J. CLIN. INVEST., vol. 91, 1993, pages 1157 - 1166 |
NORGARD ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 1068 - 1072 |
PAREKH ET AL., CURR. OP. CELL. BIOL., vol. 1, 1991, pages 750 - 754 |
ROGERS, H.W., J. IMMUNOL., vol. 156, 1996, pages 679 - 84 |
See also references of EP1947115A4 |
SPIVAK, J.; HOGANS, B., BLOOD, vol. 73, 1989, pages 90 - 99 |
WANG, S.D. ET AL., J. IMMUNOL., vol. 152, 1994, pages 5014 - 21 |
WATSON ET AL., GLYCOBIOLOGY, vol. 4, no. 2, 1994, pages 227 - 237 |
WITCHTERMAN KA; BAUNE AE; CHAUDRY IH.: "Sepsis and septic shock: a review of laboratory models and a proposal", J. SURG. RES., vol. 29, 1980, pages 189 - 201 |
WITTER, A.; HOWARD, S., BIOCHEM., vol. 29, 1990, pages 4175 - 4180 |
Also Published As
Publication number | Publication date |
---|---|
AR053416A1 (es) | 2007-05-09 |
US8343917B2 (en) | 2013-01-01 |
MA30010B1 (fr) | 2008-12-01 |
ES2396439T3 (es) | 2013-02-21 |
AU2006313672B2 (en) | 2011-12-08 |
EP1947115A2 (en) | 2008-07-23 |
US20090220595A1 (en) | 2009-09-03 |
AU2006313672A1 (en) | 2007-05-18 |
WO2007054600B1 (es) | 2007-10-18 |
WO2007054600A3 (es) | 2007-07-19 |
EP1947115B1 (en) | 2012-10-17 |
CA2629304C (en) | 2012-12-04 |
IL191279A (en) | 2012-05-31 |
CA2629304A1 (en) | 2007-05-18 |
BRPI0618498A2 (pt) | 2011-09-06 |
ZA200805044B (en) | 2009-08-26 |
MX2008006159A (es) | 2008-10-09 |
EP1947115A4 (en) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6491621B2 (ja) | 組織保護ペプチド及びその使用 | |
US9938320B2 (en) | Peptides for promoting angiogenesis and use thereof | |
EP2707014B1 (en) | High-affinity, dimeric inhibitors of psd-95 and their use for treating ischemic brain damage and pain | |
JP5208135B2 (ja) | 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物 | |
ES2398758T3 (es) | Proteína ciclica libre de cisteína | |
US9139615B2 (en) | High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain | |
WO2007054600A2 (es) | Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación | |
JP5752782B2 (ja) | 血管新生促進用ペプチド及びその使用 | |
US8372799B2 (en) | Reverse protein | |
JP2005314404A (ja) | 筋皮弁生着向上のための肝細胞増殖因子核酸配列 | |
JPH083065A (ja) | 肝臓障害に対する治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 191279 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/006159 Country of ref document: MX Ref document number: 2629304 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006820043 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006313672 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06820043 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2006313672 Country of ref document: AU Date of ref document: 20061107 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006313672 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006820043 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12093365 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0618498 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080509 |